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Objectives. The objectives of this study were to identify the randomised controlled trials in breast cancer occurring in low and
middle income countries (LMICs) generally and within Sub-Saharan Africa specifically, to describe the current status and identify
opportunities for further research in these areas.Materials and Methods. Data for this study were obtained from ClinicalTrials.gov.
The search term “Breast Cancer Research” was used, and relevant information extracted and analysed. Results. 2414 trials were
identified, of which 1099 were eligible for inclusion. 69 of these trials occurred in LMICs. Of the 52 LMICs globally, 30% were
participating in breast cancer research. Of the 17 LMICs in Africa, 77% are situated in Sub-Saharan Africa; 23% were participating
in breast cancer research, which accounted for 9% of total Sub-Saharan African studies. Conclusion. This study provides current
evidence for the need for breast cancer research in LMICs globally and within Sub-Saharan Africa. Within LMIC regions where
research is active, the type and numbers of studies are unevenly distributed. High quality research within such areas should be
encouraged as the results may have both local and global applications, particularly in the provision of affordable health care.
1. Introduction
In 2012, women from less developed countries were less
than half as likely to develop breast cancer by the age of
75 compared to those from more developed countries (8%
v 3.3%), yet almost just as likely to die from breast cancer
(1.6% v 1.2%) (see Figures 1 and 2) [1]. Safe and effective
therapies continue to be developed; however their escalating
cost means they are increasingly becoming out of reach of the
patients who need them. Howard et al. [2] emphasised this
trend by calculating the average launch price of anticancer
drugs from 1995 to 2013, adjusted for inflation and health
benefits.They found an increase of 10% annually—an average
of $8,500 per year. Considering that it is estimated that
by 2020 70% of the twenty million new cancer cases will
occur in countries that collectively have only five percent of
the global resources for cancer control [3], this trend will
have global repercussions. Lower tomiddle income countries
(LMICs) will be at the epicentre of the eruption that occurs
when the high cost of treatment, coupled with increasing
incidence rates, collideswith a lack of access and ability to pay,
unless suitable alternatives can be found. Such alternatives
have to provide affordable, simple, and widely accessible
solutions. Furthermore, in order to achieve global equality
in long term breast cancer incidence and mortality, more
evidence-based research addressing particular circumstances
in LMICs themselves is required. This will generate the
highest level of evidence in breast cancer research in LMICs
to be produced. Factors influencing incidence, access to
treatment, and mortality are to be identified and solutions
formulated and scrutinised based upon these constraints,
rather than continuing the expensive and evidence-poor cul-
ture of implementing effective treatment methods identified
in high income countries (HICs) [4].
We have prepared an overview of randomised controlled
trials currently being run in LMICs, in order to identify areas
where further research is needed.
2. Materials and Methods
A descriptive analysis was performed of all of the trials with
one or more locations in an LMIC. Data was extracted from
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Figure 1: Global breast cancer incidence andmortality in women in
2012. Estimated age-standardised rates for breast cancer incidence
(blue bar) and mortality (red bar) in females are shown for global
regions, high income regions, low income regions, and the world.
Reproduced with permission from Abenaa M Brewster, Mariana
Chavez-MacGregor, and Powel Brown. ∗ includes all regions of
Europe, Northern America, Australia, New Zealand, and Japan. †
includes all regions of Africa, Asia (excluding Japan), LatinAmerica,
the Caribbean, and Federated States of Micronesia.
ClinicalTrials.gov, a publicly available database of clinical
trials [5]. On 29 August 2016 the search term “Breast Cancer
Research” was applied to the 223,969 trials registered on
ClinicalTrials.gov. The search results were downloaded onto
a spreadsheet for tabulation and analysis. Trials with a
withdrawn status and those that did not specify that theywere
randomised were excluded.
LMICs were grouped into the geographical regions South
Asia, South East Asia, East Asia, Middle East, North Asia,
Pacifica, Africa, South America, Central America, North
America, and Europe as defined by clinicaltrials.gov, the
US Congress definition of Sub-Saharan Africa was used
(Table 1). South Sudan was not distinguished from Sudan
in the clinicaltrials.gov database. For regional analysis, each
region was selected on the website and the studies for each
LMIC within a region were downloaded. Withdrawn trials
and trials that did not specify a randomised status were
excluded. Trials were crosschecked using NCT numbers to
remove duplicates (trials listed twice or those which occurred
in more than one LMIC).
Intraregional analysis, using the spreadsheets described
above, was conducted on regions with a large number of
trials occurring in that region, to identify intraregional
distribution of trials within LMICs. Duplicate entries were
removed from the number of trials tabulated within each
LMIC in South Asia, South East Asia, North Asia, and
Africa. For interventional analysis, the regional spreadsheets
were used to determine the number of trials using each
intervention. The data extracted for each trial included the
recruitment status, study results, conditions, interventions,
sponsor/collaborators, gender, age groups, phases, enrol-
ment, source of funding, study type, first received, start
date, completion date, results first received, and primary
outcome.
3. Results
Of the initial 2414 trials, 1099 fit the criteria for inclusion
in the analysis. Trials that did not specify that they were
randomised or that had the recruitment status “withdrawn”
were excluded. 1315 trials were excluded. Trial names and
ClinicalTrials.gov identification numbers of all included trials
are listed in the Appendix.
3.1. Global Results (Tables 2 and 3). Of the 1099 trials included
in the analysis, 69 (6.3%) occurred in one or more LMICs.
Lower to middle income countries were identified 104 times
for these 69 trials.
Of the 52 LMICs identified by the World Bank (Table 1),
30.8% (16) had breast cancer research located within them.
5 (9.6%) are located in South Asia, 7 (13.5%) are located in
South East Asia, 1 (1.9%) is in East Asia, 3 (5.8%) are located in
theMiddle East, 6 (11.5%) are located in North Asia, 7 (13.5%)
are in Pacifica, 17 (32.7%) are in Africa, 1 (1.9%) is in South
America, 4 (7.7%) are in Central America, and 1 (1.9%) is in
Europe (Table 2). No LMICs are located in North America.
The percentage of LMICs that contained active breast
cancer research in each region was identified as 60% in South
Asia (3), 42.9% (3) in South East Asia, 0% in East Asia, 0%
in the Middle East, 16.7% (1) in North Asia, 0% in Pacifica,
35.3% (6) in Africa, 100% (1) in South America, 50% (2) in
Central America, and 0% in Europe (Table 3).
3.2. Intraregional Analysis. 35 breast cancer research trials
were located at 37 sites amongst the 3 LMICs of South Asia
(India, Pakistan, and Bangladesh). Of the 37 sites, 34 (91.9%)
were located in India, 2 (5.4%) were located in Pakistan, and
1 (2.7%) was located in Bangladesh. 12 breast cancer research
trials were located at 16 sites amongst the 3 active LMICs
in South East Asia (Philippines, Vietnam, and Indonesia).
Of the 16 sites, 12 (75%) were located in the Philippines, 2
(12.5%) in Vietnam, and 2 (12.5%) in Indonesia. 25 breast
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Figure 2: Global cancer statistics regarding the estimated percentage of patients with access to radiotherapy, 2012. Reproduced with
permission from Volume 65, Issue 2, pages 87–108, 4 FEB 2015. ∗ refers to countries where 100% of the population can access radiotherapy
or countries where radiotherapy is greater in supply than demand, despite possible regional differences in access to radiotherapy within the
country. Source: The Cancer Atlas, second edition, as obtained from the International Atomic Energy Agency.
Table 1: Lower-middle income economies as defined by theWorld Bank. LMICs are categorized regionally based upon clinicaltrials.gov regional
definitions. Countries written in italic font participate in RCTs in breast cancer research. Countries denoted with ∗∗ are members of Sub-
Saharan Africa (US Congress definition).
Africa South East Asia East Asia
Cabo Verde∗∗ Indonesia Mongolia
Cameroon∗∗ Lao PDR
Congo, Rep.∗∗ Myanmar Middle East
Cote d’Ivoire∗∗ Philippines Syrian Arab Republic
Djibouti∗∗ Vietnam West Bank and Gaza
Egypt, Arab Rep. Timor-Leste Yemen, Rep.
Ghana∗∗ Cambodia
Kenya∗∗ Pacifica
Lesotho∗∗ South Asia Kiribati
Mauritania∗∗ Bangladesh Micronesia, Fed. Sts.
Morocco Bhutan Papua New Guinea
Nigeria∗∗ India Samoa
Sao Tome and Principe∗∗ Pakistan Solomon Islands
Sudan∗∗ Sri Lanka Vanuatu
Swaziland∗∗ Tonga
Tunisia South America
Zambia∗∗ Bolivia Europe
Kosovo
North Asia Central America Ukraine
Armenia El Salvador
Kyrgyz Republic Guatemala
Tajikistan Honduras
Uzbekistan Nicaragua
Moldova
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Table 2:The proportion of global LMICs per region. The proportion
of LMICs in each region out of the total number of LMICs globally
(52) was calculated to determine the distribution of LMICs globally.
Regions Total regionalLMICs
Proportion of global
LMICs per region (%)
South Asia 5 9.6
South East Asia 7 13.5
East Asia 1 1.9
North Asia 6 11.5
Africa 17 32.7
South America 1 1.9
Central America 4 7.7
Europe 1 1.9
Middle East 3 5.8
Pacifica 7 13.5
Table 3: The proportion of breast cancer research active LMICs per
region. The proportion of LMICs in each region undertaking breast
cancer research was calculated to determine the distribution of
research within each region.
Regions Active researchLMICs
Active research LMICs
within region (%)
South Asia 3 60.0
South East Asia 3 42.9
East Asia 0 0.0
North Asia 1 16.7
Africa 6 35.3
South America 1 100.0
Central America 2 50.0
Europe 0 0.0
Middle East 0 0.0
Pacifica 0 0.0
cancer research trials were located at 25 LMIC sites in North
Asia; all 25 were located in Ukraine.
15 breast cancer research trials were located at 21 sites
amongst the 6 active LMICs of Africa (Morocco, Tunisia,
Egypt, Kenya, Ghana, and Nigeria). Of the 21 sites, 3 were
located inMorocco (14.3%), 1was inTunisia (4.8%), 12were in
Egypt (57.1%), 1 was in Kenya (4.8%), 1 was in Ghana (4.8%),
and 3 were in Nigeria (14.3%).
3.3. LMIC Breast Cancer Research Intervention (Table 4).
Intervention is categorised by clinicaltrials.gov as radiation,
biological, behavioural, drug, other, or combinations of these
options. For LMICs in each region, breast cancer research
using drug intervention was the most common, representing
at least 33.3% of the total breast cancer research in each
region alone, and in combination with other categories;
research containing a drug intervention represented 100% of
the research in South East Asia and North Asia and 67% of
the total breast cancer research in Central America, whilst
only 20% of African breast cancer research on LMICs was
not involving a drug intervention. Regions with the largest
numbers of breast cancer research trials occurring in LMICs
(Africa, South Asia, and North Asia) exhibited intervention
with a large focus around the drug intervention type (60.0%,
68.6%, and 65.4%, resp.) with all other intervention types
evenly distributed at a low frequency. Regions with fewer
LMIC breast cancer research trials (Central America and
East Asia) exhibited a more even distribution of intervention
type; however this was still heavily focused around the
drug intervention type. South America exhibited no drug or
associated drug intervention, with 100% of its intervention
focused on device and other intervention.
3.4. Sub-Saharan Africa. Of the 44 total countries that make
up Sub-Saharan Africa, 4 (9%) have studies located within
them (Nigeria, Kenya, Ghana, and South Africa).
Of the 17 LMICs in Africa (Table 1), 13 (76.5%) are located
in Sub-Saharan Africa (Table 1); 3 of these countries (23.1%)
contain breast cancer research.
Of the total 54 studies located at sites in Sub-Saharan
Africa, 5 (9.3%) are located in LMICs, with the remaining 49
(90.7%) located in South Africa.
Of the 6 LMICs where research is undertaken in Africa,
60% (3) are located in Sub-Saharan Africa. They account for
23.8% (5) of the total LMIC sites in Africa, and 4 (26.6%)
of the total LMIC studies in Africa. The remaining three
African LMICs are located in North Africa (Egypt, Tunisia,
and Morocco). These accounted for 16 (76.2%) of the total
sites, and 11 (73.3%) of the total studies in LMICs in Africa.
4. Discussion
Our results show that, of the 1099 trials included in the
analysis, 70 (6.4%) occurred in an LMIC, across 104 LMIC
sites. Studies are unevenly distributed amongst regions: less
than one-third of LMICs are undertaking breast cancer
research globally, and in the Middle East, Pacifica, East Asia,
and Europe there is no breast cancer research occurring in
LMICs, despite Pacifica accounting for 13.5% of the world’s
LMICs.
Although some regions, such as South Asia, have a high
percentage of breast cancer research in LMICs (60%), there
is evidence that this is monopolised by one country. For
example, 92% of the current breast cancer research studies
located in LMICs in South Asia are undertaken in India
where the healthcare expenditure per capita for 2012 is
approximately double (1.7 and 2.2 times) that of Pakistan and
Bangladesh, respectively [1]. A similar situation was found
in Africa, where three North African LMICs (Egypt, Tunisia,
and Morocco) are collectively responsible for 76% (16 of 21)
of the total LMIC studies located in Africa.
Despite making up 44 of the 51 African countries, Sub-
Saharan Africa is hugely lacking in breast cancer research.
Sub-Saharan LMICs currently account for only 9.3% of the
total studies located in Africa. Equally, only 4 (9%) of all
Sub-Saharan African countries are undertaking breast cancer
research trials. Furthermore, the distribution of total research
within Sub-Saharan Africa is distorted; for example, South
Africa undertakes 91% of the total 54 Sub-Saharan African
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Table 4: Types of intervention for RCTs in breast cancer research in LMICs in each region. The percentage for each intervention was calculated.
North America and East Asia are not included due to no LMICs being present in these regions.
Intervention South America(%)
Central America
(%)
North Asia
(%)
South East Asia
(%)
South Asia
(%)
Africa
(%)
Total number of studies 1 3 25 12 35 15
Procedure 0.0 0.0 0.0 0.0 0.0 6.7
Radiation 0.0 0.0 0.0 0.0 2.9 13.3
Other 0.0 0.0 0.0 0.0 2.9 0.0
Biological 0.0 0.0 3.8 0.0 2.9 0.0
Behavioural 0.0 0.0 0.0 0.0 2.9 0.0
Drug 0.0 33.3 65.4 58.3 68.6 60.0
Drug and radiation 0.0 0.0 0.0 0.0 2.9 0.0
Drug and procedure 0.0 0.0 11.5 33.3 2.9 13.3
Drug and procedure and radiation 0.0 0.0 0.0 0.0 2.9 0.0
Drug and procedure and other 0.0 0.0 0.0 0.0 2.9 0.0
Drug and Other 0.0 33.3 7.7 8.3 2.9 0.0
Drug and biological 0.0 0.0 11.5 0.0 5.7 6.7
Drug and behavioural 0.0 0.0 0.0 0.0 0.0 0.0
Procedure and biological 0.0 33.3 0.0 0.0 0.0 0.0
Device and other 100.0 0.0 0.0 0.0 0.0 0.0
studies, despite having a breast cancer mortality rate 2.1 times
that of Kenya, 4 times that of Ghana, and less than one-third
(29%) that ofNigeria, and a health care expenditure per capita
for 2012 15.5 times that of Kenya, 7.6 times that of Ghana, and
7 times that of Nigeria.
As identified by Elzawawy [6], national cancer con-
trol programs may be present in LMICs; however they
are global solutions implemented in countries with local
challenges, causing limited accessibility and affordability.
Chemotherapeutic-protocols from high income countries
cannot be used in low income countries due to the lack
of supportive care facilities and trained personnel. Less
intensive, less toxic, and less expensive protocols are needed
[7]. Equally, radiotherapy is highly inaccessible to most
patients in Africa. Access averages 0.89 machines per million
inhabitants compared to 8.9 per million in high income
countries [8]; 29 out of 52 African countries have no facilities
at all [9].
As highlighted by Elzawawy [6], clinical trials in LMICs
take place within the economic, social, and logistical con-
straints to healthcare found in these regions, which means
that research outcomes from trials here are applicable to
populations facing similar challenges in high income coun-
tries. At a local level, research would enable local challenges
to be identified and specific, realistic interventions to be
designed. Research in LMICs could help to ensure global
targets aremet, such as the 80% availability of affordable basic
technologies and essential medicines set by the WHO for
2020.
The repurposing of medications could also help to reach
these targets, by providing a simple, cheap, effective alter-
native that is scientifically robust as well as realistic in the
treatment of breast cancer. For example, the analgesic ketoro-
lac, a relatively inexpensive nonsteroidal anti-inflammatory
drug, given perioperatively is associated with a significantly
superior disease-free survival in the first few years after
surgery [10]. A simple treatment such as this would also be
applicable to populations who, despite living in HICs, cannot
afford therapies that aremore expensive. Akinyemiju et al. [11]
found that more than half of the African-American women
diagnosed with breast cancer studied received no radiation
or surgery as the first course of treatment despite 35% of cases
being diagnosed at stages III or IV.
Furthermore, regions such as Africa can provide large
groups of patients with a high prevalence of specific sub-
types and stages of breast cancer for research and clinical
trials. These populations are less prevalent in HICs, making
studies in these populations very difficult and expensive.
The research outcomes from such studies could be hugely
beneficial to women worldwide. For example, African female
populations present a higher proportion of triple-negative,
hormone receptor negative tumours at a later stage. Research
in these populations could provide a better understanding
of type-specific cancers but also have applications in HICs
with large populations of African ancestry. For example,
in the USA, the lifetime risk of African-American women
developing triple-negative breast cancer is almost double that
of other races [11] and accounts for 20% of the breast cancer
mortality rate in the USA despite only a 12% prevalence.
As discussed by Akinyemiju et al. [11], clinical trials
conducted in LMICs need to have clear guidance regarding
ethical conduct. Such trials must demonstrate an ethical
control arm and maintain a local aim, with the potential
of global extrapolation. With this in mind, it is ethical for
the control arm to be placebo-based, so that potential value
treatments are compared to no treatment rather than the
ideal treatment, which by definition is too expensive and
logistically convoluted to be accessed in the local community.
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It is crucial that this methodology for testing potential
treatments must only be used if such treatments can realis-
tically be implemented in the testing community. However,
to maintain long term viability, trials in LMICs must be
appropriately balanced between being ethical, beneficial to
those undertaking them and the wider community and yet
realistic in these aims, to maintain economic viability for the
sponsors.
Greater research capacity in LMICs would also bene-
fit from and enable the formation of long term research
collaborations between institutions in HICs and LMICs.
Such collaborations have been successfully established and
maintained in other research areas such as the Harvard
University and Universite’ Cheikh Anta Diop of Dakar, Sene-
gal collaboration regarding HIV/AIDS, and are beneficial
to both HICs and LMICs, HICs providing greater access to
grant funding, andmodels for research and infrastructure for
LMICs, which in turn provide regional disease experience
and knowledge, grant access, experienced public health
officials, alternative demographics, and affordable treatments
for HICs [12]. Greater breast cancer research in LMICs would
provide the opportunity for such collaborations between
LMICs and HICs to take place, stimulating both further
research in LMICs, and the production of greater clinical and
translational research, which has the potential to enhance
global understanding of breast cancer and, crucially, provide
affordable treatments.
5. Conclusions
Clearly there is insufficient research in LMICs globally.
Less than one-third of LMICs participate in randomised
controlled trials of breast cancer research; increasing the
research undertaken in LMICs is fundamental if affordable,
simple, and widely accessible healthcare treatments are to be
discovered. Research in such regions will benefit the coun-
tries themselves by providing realistic treatment solutions
that work around the constraints currently facing them. It
can also provide affordable options to people globally who
struggle to access treatments, which are rapidly increasing
in price and complexity, making them an unrealistic and
inaccessible option. In addition, LMICs enable research
into specific subtypes of disease presenting at later stages.
LMICs provide a research environment which, if harnessed,
could produce solutions to not only the healthcare prob-
lems faced in these regions, but problems faced by people
globally.
Appendix
List of trials from ClinicalTrials.gov used in this study (see
Supplementary Material available online at https://doi.org/
10.1155/2017/4259704).
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